ArticleScientific reports2026
Clinical characteristics and survival outcomes of adult inflammatory myofibroblastic tumor: a retrospective single-center study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm that can occur across all age groups and presents with heterogeneous clinical behavior. Clinical manifestations vary by tumor location and may include pain, swelling, or systemic inflammatory symptoms. Diagnosis relies on imaging and histopathological confirmation. A subset of IMTs harbor ALK gene rearrangements, supporting the use of targeted therapies. This study aimed to describe the demographic, clinical, pathological, and treatment-related characteristics of adult IMT patients, with emphasis on disease course, inflammatory markers, therapeutic responses, and survival outcomes. In this retrospective cohort, 24 patients diagnosed with IMT between 2015 and 2023 were included. Clinical features, tumor characteristics, ALK status, inflammatory markers, treatment modalities, and survival outcomes were recorded. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression methods. The median age was 31 years, and 54.2% were female. The abdomen (41.7%) and extremities (29.2%) were the most common tumor locations. Surgical resection was performed in 79.2% of patients, with R0 resection achieved in 73.7% of cases. ALK positivity was detected in 20.8% of patients. Disease progression occurred in 58.3% of the cohort. Among two patients treated with crizotinib, PFS durations were 10.0 and 17.0 months, respectively. The median PFS was 20.8 months, and the median OS was 43.5 months. Hypoalbuminemia was associated with reduced OS, while CRP and ESR did not reach statistical significance. R0 surgical resection was the strongest predictor of favorable outcomes in IMT. ALK-targeted therapy provided variable but clinically meaningful disease control. Although inflammatory markers did not consistently predict survival, abnormal values trended toward poorer outcomes. Larger multicenter studies are needed to clarify prognostic indicators and improve therapeutic strategies for this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.